Seeking Alpha

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...
Nasdaq

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

– The Company recently initiated a Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease – – Data disclosures anticipated from multiple clinical and pre-clinical ...
Nasdaq

Arvinas, Inc. Announces Upcoming Phase 3 Trials for Vepdegestrant and Progress on Multiple Clinical Programs

Arvinas plans Phase 3 trials for vepdegestrant combinations in breast cancer and initiates trials for new Parkinson's disease treatments. Arvinas, Inc. announced its plans to begin two Phase 3 ...
Monthly Prescribing Reference

Novel Meloxicam Formulation Reduces Postop Pain in Two Trials

A reduction in opioid usage over the entire treatment period was observed in patients treated with MR-107A-02 vs placebo. Topline data were announced from two phase 3 studies evaluating MR-107A-02 for ...